Literature DB >> 17917733

Antipyretic treatment of noninfectious fever in children with severe traumatic brain injury.

Jonathon M Brown1, Yuthana Udomphorn, Pilar Suz, Monica S Vavilala.   

Abstract

OBJECTIVE: The purpose of this study was to describe the treatment of noninfectious fever in children with severe traumatic brain injury (TBI).
MATERIALS AND METHODS: We conducted a retrospective study to compare type of and response to antipyretic treatment strategies in children less than or equal to 17 years and Glasgow Coma Scale (GCS) score less than 9.
RESULTS: The average admission GCS score was 4. Forty children (35 boys, 5 girls), age 7.8 +/- 5.2 years, had noninfectious fever. Seventy percent (28 of 40) received acetaminophen only, and 30% (12 of 40) received acetaminophen plus either ibuprofen or physical cooling. Time to next febrile episode was longer in patients receiving combination therapy than those receiving monotherapy (p = 0.03). Fever refractory to treatment dose or strategy occurred in more than 40% of the patients.
CONCLUSIONS: Early combination antipyretic therapy may be needed to effectively maintain normothermia in children with severe TBI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917733     DOI: 10.1007/s00381-007-0517-0

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  26 in total

1.  Clinical trial of an air-circulating cooling blanket for fever control in critically ill neurologic patients.

Authors:  S Mayer; C Commichau; N Scarmeas; M Presciutti; J Bates; D Copeland
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

2.  Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial.

Authors:  D W Dippel; E J van Breda; H M van Gemert; H B van der Worp; R J Meijer; L J Kappelle; P J Koudstaal
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

3.  Early indicators of prognosis in 846 cases of severe traumatic brain injury.

Authors:  Ji-Yao Jiang; Guo-Yi Gao; Wei-Ping Li; Ming-Kun Yu; Cheng Zhu
Journal:  J Neurotrauma       Date:  2002-07       Impact factor: 5.269

4.  The effect of brain temperature on hemoglobin extravasation after traumatic brain injury.

Authors:  Kosaku Kinoshita; Katina Chatzipanteli; Ofelia F Alonso; Mackenzie Howard; W Dalton Dietrich
Journal:  J Neurosurg       Date:  2002-10       Impact factor: 5.115

5.  Oral antipyretic therapy: evaluation of benorylate, an ester of acetylsalicylic acid and paracetamol.

Authors:  S Similä; S Keinänen; K Kouvalainen
Journal:  Eur J Pediatr       Date:  1975-12-09       Impact factor: 3.183

6.  ORAL ANTIPYRETIC THERAPY. Evaluation of aspirin-acetaminophen combination.

Authors:  R W Steele; F S Young; J W Bass; H C Shirkey
Journal:  Am J Dis Child       Date:  1972-03

7.  Effects of normothermic versus mild hyperthermic forebrain ischemia in rats.

Authors:  W D Dietrich; R Busto; I Valdes; Y Loor
Journal:  Stroke       Date:  1990-09       Impact factor: 7.914

8.  Incidence of fever in the rehabilitation phase following brain injury.

Authors:  D M Clinchot; S Otis; S C Colachis
Journal:  Am J Phys Med Rehabil       Date:  1997 Jul-Aug       Impact factor: 2.159

9.  Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.

Authors:  J He; P K Whelton; B Vu; M J Klag
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

10.  Fever in acute stroke worsens prognosis. A prospective study.

Authors:  G Azzimondi; L Bassein; F Nonino; L Fiorani; L Vignatelli; G Re; R D'Alessandro
Journal:  Stroke       Date:  1995-11       Impact factor: 7.914

View more
  1 in total

1.  The Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical Trial.

Authors:  Manoj K Saxena; Colman Taylor; Laurent Billot; Severine Bompoint; John Gowardman; Jason A Roberts; Jeffery Lipman; John Myburgh
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.